At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized Open Label Study of Sipuleucel-T vs. Sipuleucel-T and Tasquinimod in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC)
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Sipuleucel-T, and 1 other intervention for Hormone-Resistant Prostate Cancer and 3 related conditions. Completed, enrolled 2 participants across 1 site.
Detailed Summary
This randomized phase II trial studies how well sipuleucel-T with or without tasquinimod works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Tasquinimod may stop the growth of prostate cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether sipuleucel-T is more effective with or without tasquinimod in treating prostate cancer.
Study Details
Timeline
Interventions
Correlative studies
Given IV
Given PO